Stephen Resch

Deputy Director, Center for Health Decision Science
Lecturer, Department of Health Policy and Management
Harvard School of Public Health
Deputy Director, CHDS
(617) 432-1566
Home page:


Dr. Stephen Resch is the Deputy Director of the Center for Health Decision Science and a Lecturer in the Department of Health Policy and Management. He also serves as Deputy Chair of the HSPH Comparative Effectiveness Research Initiative

Dr. Resch is committed to advancing the use of decision analytic approaches in health policymaking and health program management. He frequently works with policymakers and practitioners to undertake systematic assessment of options that enhance the evidence-base for strategic decisions. Dr. Resch’s projects often focuses on synthesizing or generating evidence related to cost and impacts of various policy options to directly inform decisions of national governments and bilateral and multilateral aid organizations. Often this work involves the development or use of ‘mechanistic’ computer-based models used to simulate the outcomes of alternative policy options and estimate their health and economic consequences. When done well, the use of such tools provides decision makers with clear insights regarding trade-offs inherent to the decisions they face as well as quantitative estimates of the uncertainty in the problems they face.

Stephen Resch has conducted health economic research on a wide range of topics: policy modeling of maternal health interventions in Nigeria (PI: Sue Goldie, Sponsor: MacArthur Foundation) and Ethiopia (PI: Stephen Resch, Sponsor: CDC/PEPFAR), cost-effectiveness of a large randomized trial of WHO’s Safe Childbirth Checklist currently underway in Uttar Pradesh, India (PI: Atul Gawande, Sponsor: Bill & Melinda Gates Foundation), and cost-effectiveness of approximately 40 childhood obesity interventions in the US (PI: Steve Gortmaker, Sponsor: JPB Foundation). Currently, Dr. Resch is leading work updating estimates of HIV care costs at clinical sites in Cote d’Ivoire, South Africa, India, and Brazil for the CEPAC HIV/AIDS policy modeling project (PI: Ken Freedberg Sponsor: NIH NIAID).

Dr. Resch served as the technical lead for research commissioned by the US Office of the Global AIDS Coordinator to assess spending on HIV/AIDS programs in sub-Saharan Africa and the potential for increased domestic contribution to fill resource gaps. He also provided technical assistance to the revision of the Global Fund to Fight AIDS, TB and Malaria’s policies on eligibility, prioritization and counterpart financing, and development of its New Funding Model for allocating GFATM resources across disease areas and countries.

Dr. Resch works with the Pan American Health Organization’s ProVac Initiative on the development of spreadsheet-based tools for cost- and cost-effectiveness analysis of new vaccines and screening technologies. He often participates in in-country applications of these tools—most recently in Honduras—on a project estimating the cost of the national immunization program, as part of a multi-country immunization costing and financing study (EPIC) commissioned and coordinated by the Bill and Melinda Gates Foundation.

He teaches intermediate-level course at HSPH on economic evaluation of health programs which covers the theory and methods of conducting cost- and cost-effectiveness analysis, emphasizing persistent controversies in the field through case studies and in-class exercises.

 

Posted on April 22, 2013
Authors: Chen SC, Toy M, Yeh J, Wang JD, Resch S
Pediatrics 2013 131(4)  DOI: 10.1542/peds.2012-1262

 

OBJECTIVE:

To compare the cost-effectiveness of hepatitis B virus (HBV) control strategies combining universal vaccination with hepatitis B immunoglobulin (HBIG) treatment for neonates of carrier mothers.

METHODS:

<... (more »)
Posted on October 3, 2012
Authors: Kimmel A, Resch SC, Anglaret X, Daniels N, Goldie S, Danel C, Wong AY, Freedberg K, Weinstein M
Cost Eff Resour Alloc 2012 10(1)  DOI: 10.1186/1478-7547-10-12

BACKGROUND: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinu... (more »)

Posted on October 3, 2012
BMC Public Health 2012 12(1)  DOI: 10.1186/1471-2458-12-786

BACKGROUND: Women in Nigeria face some of the highest maternal mortality risks in the world. We explore th... (more »)

Posted on January 24, 2011
Authors: Lin JM, Resch SC, Brimmer DJ, Johnson A, Kennedy S, Burnstein N, Simon CJ
Cost Effectiveness and Resource Allocation 2011 9(1)  PubmedID: 21251294   DOI: 10.1186/1478-7547-9-1

BACKGROUND: Chronic fatigue syndrome (CFS) is a debilitating chronic illness affecting at least 4 million people in the United States. Understanding its cost improves decisions regarding resource allocation that may be direct... (more »)

Posted on November 8, 2011
Authors: Lin MM, Goldsmith JD, Resch SC, Deangelis JP, Ramappa AJ
Clin Orthop Relat Res. 2011  PubmedID: 22057818

BACKGROUND:

Many hospitals require all operative specimens be sent to pathologists for routine examination. Although previous studies indicate this practice increases medical cost, it remains unclear whether it alters patient managemen... (more »)

Posted on November 10, 2011
Authors: Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, Thorien K, Hecht R, Atun R
PLoS One 2011 6(10)  PubmedID: 21998648

Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By 2010, more than five million people began receiving antiretroviral therapy (ART) - yet each year, 2... (more »)

Posted on February 1, 2010
Authors: Regenbogen Scott E., Greenberg Caprice C., Resch Stephen C., Kollengode Anantha, Cima Robert R., Zinner Michael J., Gawande Atul A.
Surgery 2009 145(5): 527-535  PubmedID: 265655000000   ISSN/ISBN: 0039-6060   DOI: 10.1016/j.surg.2009.01.011

BACKGROUND: New technologies are available to reduce or prevent retained surgical sponges (RSS), but their relative cost effectiveness are unknown. We developed an empirically calibrated decision-analytic model comparing standard counting again... (more »)

Posted on February 10, 2010
Authors: Resch S, Kennedy S, Moore T, Rhodes W, Unlu F, Shier V, Hammett T, Snow A, Hashwani S
Abt Associates, Inc. 2007

The "overall sufficiency of planned construction [for the California Department of Corrections and Rehabilitation (CDCR)], the appropriate distribution of long-term and short-term beds, and the... (more »)

Posted on February 1, 2010
Authors: Resch Stephen C, Salomon JAoshua A, Murray Megan, Weinstein Milton C
Plos Medicine 2006 3(7): 1048-1057  PubmedID: 239493000000   ISSN/ISBN: 1549-1277   DOI: 10.1371/journal.pmed.0030241
Background Despite the existence of effective drug treatments, tuberculosis ( TB) causes 2 million deaths annually worldwide. Effective treatment is complicated by multidrug-resistant TB ( MDR TB) strains that respond only to second-line drugs. We pr... (more »)
Posted on February 1, 2010
Authors: Salomon J, Lloyd-Smith James O, Getz Wayne M, Resch S, Sanchez Maria S, Porco Travis C, Borgdorff Martien W
Plos Medicine 2006 3(8): 1302-1309  PubmedID: 240213000000   ISSN/ISBN: 1549-1277   DOI: 10.1371/journal.pmed.0030273

BACKGROUND: Development of new, effective, and affordable tuberculosis (TB) therapies has been identified as a critical priority for global TB control. As new candidates emerge from the global TB drug pipeline, the potential impacts of novel, s... (more »)

Posted on February 1, 2010
Authors: Resch S, Altice FL, Paltiel AD
Jaids-Journal of Acquired Immune Deficiency Syndromes 2005 38(2): 163-173  PubmedID: 226737000000   ISSN/ISBN: 1525-4135

Antiretroviral therapy (ART) initiated on a prenatal basis in HIV-infected pregnant women is a highly effective method for preventing mother-to-child HIV transmission. We developed a decision analytic model to project the clinical and economic ... (more »)

Posted on February 10, 2010
Authors: Clawson ML, Benson DR, Resch SC
New Zealand Journal of Botany 1997 35361-7

Frankia strains are actinomycetes that fix N2 in root nodules of plants classified in eight families of the Angiospermae. The wide variety of plants infected has raised questions about the ecology and diversity of Frankia symbion... (more »)

Instructor:
Stephen Resch
Term:
Spring 2
This course features case studies in the application of health decision science to policymaking and program management at various levels of the health system. Both developed and developing country contexts will be covered. Topics include: [1] theoretical foundations of cost-effectiveness analysis (CEA); [2] controversies and limitations of CEA in practice; [3] design and implementation of tools and protocols for measurement and valuation of cost and benefit of health programs; [4] integration of evidence of economic value into strategic planning and resource allocation decisions, performance monitoring and program evaluation; [5] the role of evidence of economic value in the context of other stakeholder criteria and political motivations.

This course features case studies in the application of health decision science to policymaking and program management at various levels of the health system. Both developed and developing country contexts will be covered. Topics include: [1] theoretical foundations of cost-effectiveness analysis (CEA); [2] controversies and limitations of CEA in practice; [3] design and implementation of tools and protocols for measurement and valuation of cost and benefit of health programs; [4] integration of evidence of economic value into strategic planning and resource allocation decisions, performance monitoring and program evaluation; [5] the role of evidence of economic value in the context of other stakeholder criteria and political motivations.

 

HPV Vaccine Policy Model

Decision models to guide the development and evaluation of HPV vaccines and diagnostics

Cost-effectiveness of Strategies to Reduce Maternal Morbidity and Mortality

There is little guidance, and few evidence based analyses, on how to cost effectively scale-up local efforts to reduce maternal mortality in the poorest countries

Global HIV/AIDS Policy Modeling

Identifying the most effective treatment strategies for HIV infection in less developed countries

Policy Modeling and Decision Tools for HIV/AIDS Program Sustainability Analysis

Synthesizing epidemiologic, health system, and financial data to generate strategic information for HIV/AIDS policymakers

ProVac: Evidence-Based Decision on New Vaccines

Collaborating to develop tools to strengthen national evidence based decisions on vaccine introduction in Latin America and the Caribbean